30s Ad: $19 - $23
60s Ad: $22 - $27
CPM Category: Health & Fitness
Different podcast categories command different CPM (cost per mille) rates based on advertiser demand and audience value.
Welcome to the Ophthalmology Innovation Podcast Where you get Candid Conversations with the Leaders and Drivers of Ophthalmic Innovation. OIS is the Largest and Original Producer of World-Class Ophthalmology Innovation Conferences and Content Since 2009.
Welcome to the Ophthalmology Innovation Podcast Where you get Candid Conversations with the Leaders and Drivers of Ophthalmic Innovation. OIS is the Largest and Original Producer of World-Class Ophthalmology Innovation Conferences and Content Since 2009.
Producers, Hosts, and Production Team
Searching
Searching for producer information... This may take a moment.
No producer information available yet. Click "Find producers" to search for the production team.
Emails, Phones, and Addresses
Contact Page Emails
Emails listed specifically on the website's official contact page.
Emails
General contact email:
oi***@healthegy.com
Phone Numbers
Customer service phone number:
(631) 565-7203
Addresses
Mailing address:
PO Box 780 Jericho, NY 11753
Form
A contact form is available on this page.
You can fill out the form at
this link.
General Website Emails
Emails found on general website pages (e.g., about, info), not the main contact page.
No website emails found.
Externally Sourced Emails
Emails discovered using automated web scraping across the internet.
No external emails found.
RSS Emails
Email addresses extracted directly from the website's or podcast's RSS feed(s).
No RSS emails found.
Recent Hosts, Guests & Topics
Here's a quick summary of the last 5 episodes on OIS Podcast | Ophthalmology's leading Podcast.
Hosts
Dr. Rob Rothman
Dr. Jai Parekh
Previous Guests
Adam Szaronos
Adam Szaronos is the CEO of IanTrek, a company focused on innovative solutions for glaucoma care. He has a rich background in the ophthalmic industry, having previously worked at Alcon and TearLab. With extensive experience in medical device sales and surgical commercialization, Adam has transitioned into C-suite leadership, where he champions new classes of glaucoma procedures. His current work at IanTrek involves the development of AloeFlow, a minimally invasive, tissue-based implant designed to activate the uveoscleral pathway, addressing unmet needs in surgical glaucoma treatment.
Adam Szaronos is the CEO of IanTrek, a company focused on innovative solutions for glaucoma care. He has a rich background in the ophthalmic industry, having previously worked at Alcon and TearLab. With extensive experience in medical device sales and surgical commercialization, Adam has transitioned into C-suite leadership, where he champions new classes of glaucoma procedures. His current work at IanTrek involves the development of AloeFlow, a minimally invasive, tissue-based implant designed to activate the uveoscleral pathway, addressing unmet needs in surgical glaucoma treatment.
Paul Smith
Paul Smith is the President and COO of Orasis Pharmaceuticals, where he leads the commercialization of innovative ophthalmic products. With over two decades of experience in the pharmaceutical industry, he has held significant roles at major companies such as Alcon and Novartis. Smith's career trajectory includes a diverse background in tech startups and ophthalmic leadership, emphasizing the importance of cross-functional experience in driving innovation. He is known for his collaborative approach and commitment to addressing unmet needs in eye care, particularly through the development of Qlosia, a novel treatment for presbyopia.
Paul Smith is the President and COO of Orasis Pharmaceuticals, where he leads the commercialization of innovative ophthalmic products. With over two decades of experience in the pharmaceutical industry, he has held significant roles at major companies such as Alcon and Novartis. Smith's career trajectory includes a diverse background in tech startups and ophthalmic leadership, emphasizing the importance of cross-functional experience in driving innovation. He is known for his collaborative approach and commitment to addressing unmet needs in eye care, particularly through the development of Qlosia, a novel treatment for presbyopia.
Andrew Gitkin
Andrew Gitkin is a prominent figure in the investment banking sector, currently associated with Leerink Partners. He specializes in healthcare investments, particularly in the biotech and ophthalmology fields, providing insights and strategic advice to clients navigating the complexities of capital markets.
Andrew Gitkin is a prominent figure in the investment banking sector, currently associated with Leerink Partners. He specializes in healthcare investments, particularly in the biotech and ophthalmology fields, providing insights and strategic advice to clients navigating the complexities of capital markets.
Cameron Taylor
Cameron Taylor is a leading investment banker at Bank of America, focusing on the healthcare sector. With extensive experience in financial advisory and capital raising, he plays a crucial role in guiding biotech companies through market challenges and opportunities.
Cameron Taylor is a leading investment banker at Bank of America, focusing on the healthcare sector. With extensive experience in financial advisory and capital raising, he plays a crucial role in guiding biotech companies through market challenges and opportunities.
Susan Orr, PhD
Dr. Susan Orr is a seasoned expert in the biotech industry, currently with Claris Bio. She holds a PhD and has a strong background in ophthalmology research and development, contributing to innovative solutions in the field.
Dr. Susan Orr is a seasoned expert in the biotech industry, currently with Claris Bio. She holds a PhD and has a strong background in ophthalmology research and development, contributing to innovative solutions in the field.
Anupam Dalal, MD
Dr. Anupam Dalal is a medical doctor and investment professional at Acuta Capital. He combines his medical expertise with financial acumen to identify and invest in promising biotech ventures, particularly in ophthalmology.
Dr. Anupam Dalal is a medical doctor and investment professional at Acuta Capital. He combines his medical expertise with financial acumen to identify and invest in promising biotech ventures, particularly in ophthalmology.
Dr. Pravin Dugel
Dr. Pravin Dugel is the Chairman and CEO of Ocular Therapeutix, a company focused on developing innovative therapies for ophthalmic conditions. With a strong background in clinical practice and research, he is a recognized leader in the ophthalmology field.
Dr. Pravin Dugel is the Chairman and CEO of Ocular Therapeutix, a company focused on developing innovative therapies for ophthalmic conditions. With a strong background in clinical practice and research, he is a recognized leader in the ophthalmology field.
Michael ORourke
Michael ORourke is the CEO of Re-Vana Therapeutics, a company focused on developing innovative drug delivery solutions for ophthalmic applications. With a background in biotechnology and a strong track record in the pharmaceutical industry, ORourke has been instrumental in advancing the company's proprietary hydrogel-based technologies aimed at providing longer-lasting treatments for retinal diseases. Under his leadership, Re-Vana has raised significant funding to support its clinical and development strategies, positioning itself as a leader in the field of sustained-release biologics.
Michael ORourke is the CEO of Re-Vana Therapeutics, a company focused on developing innovative drug delivery solutions for ophthalmic applications. With a background in biotechnology and a strong track record in the pharmaceutical industry, ORourke has been instrumental in advancing the company's proprietary hydrogel-based technologies aimed at providing longer-lasting treatments for retinal diseases. Under his leadership, Re-Vana has raised significant funding to support its clinical and development strategies, positioning itself as a leader in the field of sustained-release biologics.
Andrew Stewart
Andrew Stewart is a seasoned executive with over 25 years of experience in the pharmaceutical industry. He has held leadership positions at prominent companies such as Bausch + Lomb, AbbVie, and Allergan. His extensive background in global business management has significantly influenced innovation in eye care, making him a respected figure in the field.
Andrew Stewart is a seasoned executive with over 25 years of experience in the pharmaceutical industry. He has held leadership positions at prominent companies such as Bausch + Lomb, AbbVie, and Allergan. His extensive background in global business management has significantly influenced innovation in eye care, making him a respected figure in the field.
Anthony Wallace
Anthony Wallace is a healthcare veteran with 26 years of experience in the industry. He has served in leadership roles at major pharmaceutical companies including Novartis, Merck, and GlaxoSmithKline. Currently, he leads Bausch + Lomb's U.S. Surgical business and is known for his commitment to patient-centered solutions and advancing ophthalmic care.
Anthony Wallace is a healthcare veteran with 26 years of experience in the industry. He has served in leadership roles at major pharmaceutical companies including Novartis, Merck, and GlaxoSmithKline. Currently, he leads Bausch + Lomb's U.S. Surgical business and is known for his commitment to patient-centered solutions and advancing ophthalmic care.
Topics Discussed
uveoscleral pathway
glaucoma
bio-interventional innovation
AloeFlow
medical device sales
surgical commercialization
C-suite leadership
material science breakthrough
post-MiGs patients
medtech
presbyopia
Qlosia
FDA-approved
low-dose pilocarpine
Orasis Pharmaceuticals
ophthalmic innovation
go-to-market strategy
optometry
patient needs
ophthalmic industry
investment
banking
biotech
macroeconomic shifts
regulatory confidence
capital markets
market volatility
early-stage biotech
high-quality innovation
strategic interest
wet AMD
GA
dry AMD
geographic atrophy
sustained drug delivery
ophthalmology
intravitreal injections
retinal diseases
AMD
biodegradable drug implants
EyeLief
OcuLief
patient compliance
clinical strategy
investment strategy
Series B raise
retinal therapeutics
pharmaceutical leadership
eye care
patient-centered solutions
organizational culture
global ophthalmology markets
leadership
mentorship
The Ophthalmology Innovation Summit (OIS) was conceptualized and designed by ophthalmologist/venture capitalist Emmett Cunningham of Clarus Ventures. To make his vision for OIS a reality, Emmett partnered with legendary venture capitalists Bill Link of Versant Ventures and fellow ophthalmologist/venture capitalist Gil Kliman of InterWest Partners to Co-Champion the programs. The final addition of experienced event producer Craig Simak brought the event to life. Their combined efforts have resulted in the OIS franchise which has attracted thousands of industry leaders within the ophthalmic space since the first meeting in 2009.
The OIS programs are presented annually by Healthegy, Inc. as affiliate meetings with AAO and ASCRS.
In this edition of The Rob & Jai Show, the OIS Podcast welcomes Adam Szaronos, CEO of IanTrek, for a wide-ranging conversation on innovation, leadership, and unlocking new pathways in glaucoma care. Adam walks us through his career journey from Alcon to TearLab to leading IanTrek, where he’s now championing a new class of glaucoma procedures with AloeFlow™—a minimally invasive, tissue-based implant that activates the uveoscleral pathway.
Together with hosts Dr. Rob Rothman and Dr. Jai Parekh, Adam discusses:
The evolution of his career from medical device sales to surgical commercialization and C-suite leadership.
Why the uveoscleral pathway, long leveraged in pharmacology, has remained unaddressed in surgical glaucoma—and how IanTrek is changing that.
The material science breakthrough that differentiates AloeFlow™ from past uveoscleral attempts like CyPass.
The market opportunity for post-MiGs patients and how IanTrek’s platform opens new treatment options without burning surgical real estate.
Insights into IanTrek’s growing bio-interventional pipeline and what’s ahead in 2025 and beyond.
Whether you’re a glaucoma surgeon, an investor, or a medtech strategist, this episode is a must-listen on where glaucoma innovation is headed.
Subscribe to the OIS Podcast today and stay connected to the future of ophthalmology.
In this edition of The Rob & Jai Show, the OIS Podcast welcomes Adam Szaronos, CEO of IanTrek, for a wide-ranging conversation on innovation, leadership, and unlocking new pathways in glaucoma care. Adam walks us through his career journey from Alcon to TearLab to leading IanTrek, where he’s now championing a new class of glaucoma procedures with AloeFlow™—a minimally invasive, tissue-based implant that activates the uveoscleral pathway.
Together with hosts Dr. Rob Rothman and Dr. Jai Parekh, Adam discusses:
The evolution of his career from medical device sales to surgical commercialization and C-suite leadership.
Why the uveoscleral pathway, long leveraged in pharmacology, has remained unaddressed in surgical glaucoma—and how IanTrek is changing that.
The material science breakthrough that differentiates AloeFlow™ from past uveoscleral attempts like CyPass.
The market opportunity for post-MiGs patients and how IanTrek’s platform opens new treatment options without burning surgical real estate.
Insights into IanTrek’s growing bio-interventional pipeline and what’s ahead in 2025 and beyond.
Whether you’re a glaucoma surgeon, an investor, or a medtech strategist, this episode is a must-listen on where glaucoma innovation is headed.
Subscribe to the OIS Podcast today and stay connected to the future of ophthalmology.
0:0036:21
Bringing Presbyopia Back to the Forefront: Paul Smith of Orasis on The Rob & Jai Show, an Edition of the OIS Podcast
In this edition of The Rob & Jai Show, Paul Smith, President & COO of Orasis Pharmaceuticals, joins Dr. Rob Rothman and Dr. Jai Parekh for a compelling conversation on his career path and the commercialization of Qlosi™—a novel, FDA-approved, low-dose pilocarpine eye drop for the treatment of presbyopia.
With more than two decades of experience across Alcon, Novartis, and now Orasis, Smith reflects on his unique career trajectory from tech startups to ophthalmic leadership, the importance of cross-functional experience, and how a shared vision with founder & CEO Elad Kedar led him to the helm of a company now reshaping the presbyopia landscape.
In this episode, you'll learn:
Why Qlosi™ was formulated at the lowest approved concentration of pilocarpine to prioritize safety, tolerability, and functional vision.
How Orasis is differentiating its launch by learning from past category efforts and focusing on real-world expectations and patient needs.
The company’s go-to-market strategy, including a hybrid access model and the role of optometry in driving adoption.
Why Paul believes innovation in eye care thrives on collaboration, humility, and continuous learning.
What makes presbyopia such a powerful entry point into the broader continuum of vision care.
With a clear mission, strong leadership, and a product designed with patients in mind, Orasis is setting a new standard in treating one of the most common unmet needs in eye care.
Don’t miss this thoughtful and inspiring discussion—subscribe to the OIS Podcast today to stay ahead of what’s next in ophthalmic innovation!
In this edition of The Rob & Jai Show, Paul Smith, President & COO of Orasis Pharmaceuticals, joins Dr. Rob Rothman and Dr. Jai Parekh for a compelling conversation on his career path and the commercialization of Qlosi™—a novel, FDA-approved, low-dose pilocarpine eye drop for the treatment of presbyopia.
With more than two decades of experience across Alcon, Novartis, and now Orasis, Smith reflects on his unique career trajectory from tech startups to ophthalmic leadership, the importance of cross-functional experience, and how a shared vision with founder & CEO Elad Kedar led him to the helm of a company now reshaping the presbyopia landscape.
In this episode, you'll learn:
Why Qlosi™ was formulated at the lowest approved concentration of pilocarpine to prioritize safety, tolerability, and functional vision.
How Orasis is differentiating its launch by learning from past category efforts and focusing on real-world expectations and patient needs.
The company’s go-to-market strategy, including a hybrid access model and the role of optometry in driving adoption.
Why Paul believes innovation in eye care thrives on collaboration, humility, and continuous learning.
What makes presbyopia such a powerful entry point into the broader continuum of vision care.
With a clear mission, strong leadership, and a product designed with patients in mind, Orasis is setting a new standard in treating one of the most common unmet needs in eye care.
Don’t miss this thoughtful and inspiring discussion—subscribe to the OIS Podcast today to stay ahead of what’s next in ophthalmic innovation!
0:0031:58
The View from the Street: Industry Trends, Strategic Shifts & Navigating Uncertainty
Guests
Guests of this podcast episode
Andrew GitkinCameron TaylorSusan Orr, PhDAnupam Dalal, MDDr. Pravin Dugel
In this edition of the OIS Podcast, a powerhouse panel of investment, banking, and biotech leaders offers unfiltered insights on the current and future state of the ophthalmic industry. Featuring Andrew Gitkin (Leerink Partners), Cameron Taylor (Bank of America), Susan Orr, PhD (Claris Bio), and Anupam Dalal, MD (Acuta Capital), and Dr. Pravin Dugel, Chairman and CEO of Ocular Therapeutix, this session explores how macroeconomic and political shifts—such as RFK Jr.'s FDA rhetoric and rising interest rates—are influencing capital markets, regulatory confidence, and biotech strategy.
With humor, candor, and deep expertise, the panel discusses:
🔹The real impact of market volatility and regulatory speculation on investment in early-stage biotech. 🔹Why high-quality innovation still commands attention, even in uncertain times. 🔹How strategic interest in ophthalmology is evolving, and why later-stage assets may be getting more attention. 🔹Why board functionality may be the most underappreciated variable in getting a deal done. 🔹Trends in wet AMD, GA, and the wide-open opportunities in dry AMD and geographic atrophy.
If you’re a startup navigating today’s market, an investor looking for the next big breakthrough, or a strategist planning your pipeline, this is one episode you can’t afford to miss.
Don’t miss this compelling conversation. Subscribe to the OIS Podcast today and stay connected to the future of ophthalmology.
In this edition of the OIS Podcast, a powerhouse panel of investment, banking, and biotech leaders offers unfiltered insights on the current and future state of the ophthalmic industry. Featuring Andrew Gitkin (Leerink Partners), Cameron Taylor (Bank of America), Susan Orr, PhD (Claris Bio), and Anupam Dalal, MD (Acuta Capital), and Dr. Pravin Dugel, Chairman and CEO of Ocular Therapeutix, this session explores how macroeconomic and political shifts—such as RFK Jr.'s FDA rhetoric and rising interest rates—are influencing capital markets, regulatory confidence, and biotech strategy.
With humor, candor, and deep expertise, the panel discusses:
🔹The real impact of market volatility and regulatory speculation on investment in early-stage biotech. 🔹Why high-quality innovation still commands attention, even in uncertain times. 🔹How strategic interest in ophthalmology is evolving, and why later-stage assets may be getting more attention. 🔹Why board functionality may be the most underappreciated variable in getting a deal done. 🔹Trends in wet AMD, GA, and the wide-open opportunities in dry AMD and geographic atrophy.
If you’re a startup navigating today’s market, an investor looking for the next big breakthrough, or a strategist planning your pipeline, this is one episode you can’t afford to miss.
Don’t miss this compelling conversation. Subscribe to the OIS Podcast today and stay connected to the future of ophthalmology.
0:0013:44
Breaking Barriers in Sustained Drug Delivery: Michael O’Rourke on The Rob & Jai Show edition of the OIS Podcast
Hosts
Hosts of this podcast episode
Dr. Rob RothmanDr. Jai Parekh
Guests
Guests of this podcast episode
Michael ORourke
Keywords
Keywords of this podcast episode
sustained drug deliveryophthalmologyintravitreal injectionsretinal diseasesAMDbiodegradable drug implantsEyeLiefOcuLiefpatient complianceclinical strategyinvestment strategySeries B raiseretinal therapeutics
In this episode of The Rob & Jai Show, Michael O’Rourke, CEO of Re-Vana Therapeutics, joins Dr. Rob Rothman and Dr. Jai Parekh to explore the next-generation of sustained drug delivery in ophthalmology. With millions of intravitreal injections administered annually for retinal diseases like AMD, the need for longer-lasting, more effective treatments has never been greater.
O’Rourke explains how Re-Vana’s proprietary hydrogel-based technologies are setting a new standard for biodegradable, sustained-release drug implants—offering six to twelve months of therapeutic coverage without the need for surgery. The discussion covers:
🔹How Re-Vana’s EyeLief™ and OcuLief™ technologies work to deliver biologics efficiently over extended periods. 🔹Why reducing injection frequency is critical for patient compliance, physician workflow, and overall treatment success. 🔹 The company’s clinical and investment strategy, including a $70M Series B raise to advance its lead asset, a six-month biodegradable fluocinolone acetonide implant. 🔹 The role of strategic partnerships in accelerating innovation, as major pharma companies seek delivery solutions for their retinal therapeutics. 🔹 The global impact of sustained-release biologics, and how Re-Vana is positioning itself as a leader in both the U.S. and European markets.
With a team of seasoned industry experts, strong investor backing, and an unwavering commitment to innovation, Re-Vana Therapeutics is redefining how we approach retinal disease treatment.
Don’t miss this insightful conversation—subscribe to the OIS podcast today and stay ahead of the curve in ophthalmic innovation!
In this episode of The Rob & Jai Show, Michael O’Rourke, CEO of Re-Vana Therapeutics, joins Dr. Rob Rothman and Dr. Jai Parekh to explore the next-generation of sustained drug delivery in ophthalmology. With millions of intravitreal injections administered annually for retinal diseases like AMD, the need for longer-lasting, more effective treatments has never been greater.
O’Rourke explains how Re-Vana’s proprietary hydrogel-based technologies are setting a new standard for biodegradable, sustained-release drug implants—offering six to twelve months of therapeutic coverage without the need for surgery. The discussion covers:
🔹How Re-Vana’s EyeLief™ and OcuLief™ technologies work to deliver biologics efficiently over extended periods. 🔹Why reducing injection frequency is critical for patient compliance, physician workflow, and overall treatment success. 🔹 The company’s clinical and investment strategy, including a $70M Series B raise to advance its lead asset, a six-month biodegradable fluocinolone acetonide implant. 🔹 The role of strategic partnerships in accelerating innovation, as major pharma companies seek delivery solutions for their retinal therapeutics. 🔹 The global impact of sustained-release biologics, and how Re-Vana is positioning itself as a leader in both the U.S. and European markets.
With a team of seasoned industry experts, strong investor backing, and an unwavering commitment to innovation, Re-Vana Therapeutics is redefining how we approach retinal disease treatment.
Don’t miss this insightful conversation—subscribe to the OIS podcast today and stay ahead of the curve in ophthalmic innovation!
0:0024:25
Industry Titans Talk Ophthalmic Innovation: Andrew Stewart & Anthony Wallace on the Rob & Jai Show
In this episode of The Rob & Jai Show, Dr. Rob Rothman and Dr. Jai Parekh host a captivating conversation with Andrew Stewart and Anthony Wallace—two leaders who are among the most experienced and admired executives in ophthalmology. Andrew Stewart, with over 25 years of pharmaceutical leadership across Bausch + Lomb, AbbVie, and Allergan, shares how his global business acumen shapes innovation in eye care. Anthony Wallace, a 26-year healthcare veteran with leadership roles at Novartis, Merck, and GlaxoSmithKline, reflects on leading Bausch + Lomb’s U.S. Surgical business and his passion for patient-centered solutions. Both leaders bring a wealth of knowledge, relatable stories, and a shared commitment to advancing ophthalmic care.
In this episode, you’ll learn: 🔹How Andrew Stewart and Anthony Wallace’s extensive pharmaceutical backgrounds influence their leadership in ophthalmology. 🔹Key trends shaping the future of pharmaceutical and surgical innovations in eye care. 🔹Insights into fostering strong organizational cultures that prioritize patient outcomes. 🔹Strategies for navigating the complexities of global ophthalmology markets. 🔹Personal reflections on leadership, mentorship, and maintaining passion for patient impact.
Don't miss this inspiring conversation with two leaders whose expertise, warmth, and dedication continue to shape the future of ophthalmology. Subscribe to the OIS podcast today and stay ahead of the curve in eye care innovation!
In this episode of The Rob & Jai Show, Dr. Rob Rothman and Dr. Jai Parekh host a captivating conversation with Andrew Stewart and Anthony Wallace—two leaders who are among the most experienced and admired executives in ophthalmology. Andrew Stewart, with over 25 years of pharmaceutical leadership across Bausch + Lomb, AbbVie, and Allergan, shares how his global business acumen shapes innovation in eye care. Anthony Wallace, a 26-year healthcare veteran with leadership roles at Novartis, Merck, and GlaxoSmithKline, reflects on leading Bausch + Lomb’s U.S. Surgical business and his passion for patient-centered solutions. Both leaders bring a wealth of knowledge, relatable stories, and a shared commitment to advancing ophthalmic care.
In this episode, you’ll learn: 🔹How Andrew Stewart and Anthony Wallace’s extensive pharmaceutical backgrounds influence their leadership in ophthalmology. 🔹Key trends shaping the future of pharmaceutical and surgical innovations in eye care. 🔹Insights into fostering strong organizational cultures that prioritize patient outcomes. 🔹Strategies for navigating the complexities of global ophthalmology markets. 🔹Personal reflections on leadership, mentorship, and maintaining passion for patient impact.
Don't miss this inspiring conversation with two leaders whose expertise, warmth, and dedication continue to shape the future of ophthalmology. Subscribe to the OIS podcast today and stay ahead of the curve in eye care innovation!
Ratings
Global:
Global ratings are aggregates of the individual countries